ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

While molnupiravir and nirmatrelvir-ritonavir were developed for treatment of mild to moderate COVID-19 infection, there has been lack of data on the efficacy among unvaccinated adult patients with chronic respiratory diseases, including asthma, COPD and bronchiectasis.

A territory-wide retrospective cohort study on the efficacy of molnupiravir and nirmatrelvir-ritonavir against COVID-19 infection in unvaccinated adult patients with chronic respiratory diseases.

Total 3267 patients were included. Nirmatrelvir-ritonavir was effective in preventing respiratory failure (66.6%; 95% CI, 25.6-85.0%, p=0.007), severe respiratory failure (77.0%; 95% CI, 6.9?94.3%, p=0.039) with statistical significance and probably COVID-19 related hospitalization (43.9%; 95% CI, -1.7-69.0%, p=0.057) and in-hospital mortality (62.7%; 95% CI, -0.6?86.2, p=0.051) with borderline statistical significance. Molnupiravir was effective in preventing COVID-19 related severe respiratory failure (48.2%; 95% CI 0.5?73.0, p=0.048) and in-hospital mortality with anti-viral effectiveness of and (58.3%; 95% CI, 22.9 ? 77.4, p=0.005).

Nirmatrelvir-ritonavir and molnupiravir are effective in preventing COVID-19 related severe respiratory failure. Nirmatrelvir-ritonavir have extra benefits in preventing COVID-19 related respiratory failure among unvaccinated adult patients with chronic respiratory diseases and probably COVID-19 related hospitalization.

Abstract

#{title}